"Manufacturer Withdraws ALS Drug from Market After Failed Clinical Trial"

Amylyx, the maker of the ALS drug Relyvrio, is pulling the drug from the market and laying off 70% of its workforce after a large clinical trial showed the drug did not help patients. The drug, approved by the FDA in September 2022, failed to meet its goals in a 48-week trial involving 664 patients, leading to its withdrawal from the market. Patients already taking the medication can continue through a free drug program, but it is no longer available to new patients. Amylyx is now focusing on other drug candidates for neurodegenerative diseases and will lay off most of its employees.